详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Ji Jiafu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] * ; Liang Han[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Xue Yingwei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Shen Lin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Wang Yanong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhou Zhiwei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Yu Jiren[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Du Yian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Li Guoli[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Chen Lin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Xiao Gan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Wu Dan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Dang Chengxue[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhou Yanbing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; He Yulong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhang Zhongtao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Li Yong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Li Ziyu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhang Xiaotian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ;

机构： [1]Peking University Cancer Hospital and Institute, Beijing, China [2]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [3]Harbin Medical University Cancer Hospital, Harbin, China [4]Department of GI Oncology, Peking University Cancer Hospital, Beijing, China [5]Fudan University Shanghai Cancer Center, Shanghai, China [6]Sun Yat-Sen University Cancer Center, Guangzhou, China [7]The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China [8]Zhejiang Cancer Hospital, Hangzhou, China [9]Nanjing General Hospital of Nanjing Military Command, Nanjing, China [10]Chinese PLA General Hospital, Beijing, China [11]Beijing Hospital, Beijing, China [12]2nd Affiliated Hospital of Zhejiang University, Hangzhou, China [13]Department of Oncology Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China [14]The Affiliated Hospital of Qingdao University Medical College, Qingdao, China [15]The First Affiliated Hospital, Sun Yat-San University, Guangzhou, China [16]Beijing Friendship Hospital, Beijing, China [17]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [18]Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

第一作者：

第一作者机构： [1]Peking University Cancer Hospital and Institute, Beijing, China [2]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [3]Harbin Medical University Cancer Hospital, Harbin, China [4]Department of GI Oncology, Peking University Cancer Hospital, Beijing, China [5]Fudan University Shanghai Cancer Center, Shanghai, China [6]Sun Yat-Sen University Cancer Center, Guangzhou, China [7]The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China [8]Zhejiang Cancer Hospital, Hangzhou, China [9]Nanjing General Hospital of Nanjing Military Command, Nanjing, China [10]Chinese PLA General Hospital, Beijing, China [11]Beijing Hospital, Beijing, China [12]2nd Affiliated Hospital of Zhejiang University, Hangzhou, China [13]Department of Oncology Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China [14]The Affiliated Hospital of Qingdao University Medical College, Qingdao, China [15]The First Affiliated Hospital, Sun Yat-San University, Guangzhou, China [16]Beijing Friendship Hospital, Beijing, China [17]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [18]Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Peri/post-operative chemotherapy of oxaliplatin combined with S-1 (SOX) versus post-operative oxaliplatin with capecitabine (XELOX) in locally advanced gastric cancer: RESOLVE Trial.

文献详情